

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州藥業股份有限公司

Guangzhou Pharmaceutical Company Limited

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ANNOUNCEMENT OF WRITTEN RESOLUTIONS PASSED BY THE FIFTH SESSION OF THE BOARD

The fifth session of the board of directors (the “Board”) of Guangzhou Pharmaceutical Company Limited (the “Company”) has passed the following resolutions by way of written resolutions on 26 March 2012:

1. The resolution on amendments to the code of practice of the Audit Committee of the Board of Guangzhou Pharmaceutical Company Limited (the text of which has been published on the website of The Shanghai Stock Exchange (the “SSE”) and The Stock Exchange of Hong Kong Limited (the “HKEx”));
2. The resolution on amendments to the implementing regulations for the nomination and remuneration committee of the Board of Guangzhou Pharmaceutical Company Limited (the text of which has been published on the website of the SSE and the HKEx);
3. The resolution on the procedures for shareholders to propose a person for election as a director of the Company (the text of which has been published on the Company’s website);
4. The resolution on shareholders’ communications policy of Guangzhou Pharmaceutical Company Limited;
5. The resolution on the Board is responsible for performing the corporate governance functions of the Company in accordance with the terms of reference of corporate governance functions of the Board as set out in the Corporate Governance Code and Corporate Governance Report contained in the Appendix 14 to the Rules Governing the Listing of Securities on the HKEx. The Board agreed to adopt the code provisions as set out in the Corporate Governance Code and Corporate Governance Report contained in Appendix 14 to the Rules Governing the Listing of Securities on the HKEx and to approve to take necessary actions in compliance with the said code provisions.

This announcement is made pursuant to Rule 13.09 (2) of the Rules Governing the Listing of Securities on the HKEx.

The Board of
Guangzhou Pharmaceutical Company Limited

Guangzhou, the PRC, 27 March 2012

As at the date of this announcement, the Board comprises Mr. Yang Rongming, Mr. Li Chuyuan, Mr. Shi Shaobin and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.